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Abstract
Background: Most information on invasive Staphylococcus aureus infections comes from temperate countries. There are
considerable knowledge gaps in epidemiology, treatment, drug resistance and outcome of invasive S. aureus infection in
the tropics.
Methods: A prospective, observational study of S. aureus bacteraemia was conducted in a 1000-bed regional hospital in
northeast Thailand over 1 year. Detailed clinical data were collected and final outcomes determined at 12 weeks, and
correlated with antimicrobial susceptibility profiles of infecting isolates.
Principal Findings: Ninety-eight patients with S. aureus bacteraemia were recruited. The range of clinical manifestations was
similar to that reported from temperate countries. The prevalence of endocarditis was 14%. The disease burden was highest
at both extremes of age, whilst mortality increased with age. The all-cause mortality rate was 52%, with a mortality
attributable to S. aureus of 44%. Methicillin-resistant S. aureus (MRSA) was responsible for 28% of infections, all of which
were healthcare-associated. Mortality rates for MRSA and methicillin-susceptible S. aureus (MSSA) were 67% (18/27) and 46%
(33/71), respectively (p=0.11). MRSA isolates were multidrug resistant. Only vancomycin or fusidic acid would be suitable as
empirical treatment options for suspected MRSA infection.
Conclusions: S. aureus is a significant pathogen in northeast Thailand, with comparable clinical manifestations and a similar
endocarditis prevalence but higher mortality than industrialised countries. S. aureus bacteraemia is frequently associated
with exposure to healthcare settings with MRSA causing a considerable burden of disease. Further studies are required to
define setting-specific strategies to reduce mortality from S. aureus bacteraemia, prevent MRSA transmission, and to define
the burden of S. aureus disease and emergence of drug resistance throughout the developing world.
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Introduction
The published literature on invasive Staphylococcus aureus disease
is heavily skewed towards industrialised temperate countries,
where it represents a major cause of community- and hospital-
acquired infection [1,2]. Clinical management has been compli-
cated by the increasing proportion of infections caused by
methicillin-resistant S. aureus (MRSA), a problem that was initially
limited to hospital-adapted strains but that has now extended to
community-associated strains [3,4]. Attributable mortality rates for
S. aureus bacteraemia (SAB) in the developed world are typically up
to 30% [5–7], and the costs of treating nosocomial infection,
screening for MRSA carriage and changes in prescribing practices
to include cover for MRSA are considerable. This situation has
attracted huge public and media attention and receives significant
research funding.
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developing world, where S. aureus is considered to be a less
important cause of morbidity and mortality than other infectious
diseases such as pneumococcal infections, malaria, HIV infection
and tuberculosis. There are few studies of S. aureus infection in
tropical countries that define disease epidemiology, the nature of
clinical manifestations, outcome and drug resistance patterns. Yet
the spread of pandemic clones of MRSA has major implications
for the developing world, where facilities to determine antimicro-
bial resistance are lacking, expensive antibiotics required to treat
MRSA are often not available and hospital infection control
policies are limited. The availability of over-the-counter antibiotics
in much of the tropical world is likely to be a major driver of drug
resistance.
Here, we begin to fill our knowledge gaps with a study that
describes the epidemiology, treatment and outcome from S. aureus
bacteraemia in northeast Thailand, together with the incidence,
place of acquisition and impact of MRSA infections.
Methods
Patients and Clinical methods
The Ethical and Scientific Review sub-committee of the Royal
Thai Government Ministry of Public Health, and the Oxford
Tropical Research Ethics Committee both approved the study. A
prospective, observational study was conducted at Sappasithipra-
song Hospital in northeast Thailand for a period of 1 year, from
November 2006 to November 2007. This 1000-bed regional
hospital has a catchment of 2 million people, the majority of whom
are rice farmers and their families. The hospital provides a
comprehensive clinical and laboratory service. Potential study
patients were identified by daily screening of the blood culture
results in the hospital diagnostic microbiology laboratory. Patients
of any age with at least one clinically significant blood culture
positive for a pure growth of S. aureus were enrolled into the study
after providing written informed consent. Following recruitment,
study investigators visited inpatients daily until discharge to record
progress and management. Data were recorded on standardised
forms adapted from those developed by Fowler et al [8]. Clinical
care was provided by the hospital physicians, independent of the
research team. Study-specific investigations were a repeat blood
culture taken 48–96 hours after the first culture positive for S.
aureus and a transthoracic echocardiogram. Results of study
investigations were given to hospital physicians caring for the
patient. Echocardiograms on patients aged less than 14 years were
performed by a paediatric echocardiographer (T.W.), while
echocardiograms on the remainder were performed and/or
reviewed by study investigators trained in adult echocardiography
(E.K.N., W.M., H.B.). Final outcome was determined 12 weeks
from the date the first culture positive for S. aureus was taken using
a standardised telephone questionnaire.
Definitions
Community-acquired infection was defined as admission to
hospital with an illness consistent with invasive S. aureus disease and
a positive S. aureus blood culture. Nosocomial infection was defined
as a positive S. aureus blood culture taken more than 48 hours after
admission for another condition. Non-nosocomial healthcare-
associated infection was defined as community-acquired infection
above but in an individual who had been in contact with
healthcare services in the preceding year, using the criteria
described by Fowler et al [8]. Sites of S. aureus infection were
established based on examination findings and referral to the
medical notes, including investigation reports and operation notes.
A history of an underlying chronic medical condition was recorded
if documented in the medical notes. Outcomes at 12 weeks were
defined as: (i) cure - clinically improved and no additional sites of
infection present or suspected; (ii) unresolved infection - persistent
features of infection with or without persistent positive cultures; (iii)
death attributable to S. aureus - when death was due to S. aureus
infection in a previously healthy individual or when S. aureus
hastened death in the presence of an underlying condition such as
cancer; or (iv) death due to other causes - when the S. aureus
infection did not appear to contribute to death.
Laboratory methods
Antibiotic susceptibilities were performed by the hospital
microbiology laboratory using the disk diffusion method [9].
Susceptibilities reported to hospital physicians were penicillin,
oxacillin, cefazolin, erythromycin, clindamycin and trimethoprim-
sulphamethoxazole for methicillin-susceptible S. aureus (MSSA).
For MRSA isolates, susceptibilities to vancomycin and fusidic acid
were added. A total of 81/98 S. aureus isolates were available for
further study, re-identified and stored at 280uC. An extended
antibiotic susceptibility profile was determined in our research
laboratory at the hospital using the disk diffusion method [9] to
establish susceptibilities to other antibiotic agents with potential
activity against the clinical isolates. This panel included cefoxitin,
chloramphenicol, ciprofloxacin, clindamycin, erythromycin, fusi-
dic acid, gentamicin, mupirocin, netilmicin, penicillin, rifampicin,
trimethoprim-sulphamethoxazole, tetracycline and vancomycin.
Isolates that were resistant to cefoxitin by disk diffusion were
evaluated by oxacillin and vancomycin E-tests (AB Biodisk).
Isolates were designated as MRSA based on an oxacillin E-test for
81 isolates, and based on the oxacillin disk diffusion assay
performed by the hospital laboratory for the 17 isolates that were
not available for further testing.
Statistical analysis
Data were double entered into a database. Data analysis was
performed using Stata software version 9 (StataCorp, College
Station, Texas). Categorical data were analysed using Fisher’s
exact test and for continuous data the Mann-Whitney U test was
used. Reported p values are two-tailed. Kaplan-Meier survival
curves were plotted for attributable and non-attributable deaths,
and for S. aureus attributable deaths in children and adults (non-
attributable deaths censored). These survival curves were com-
pared using the log rank test.
Results
Patient characteristics
A total of 106 patients fulfilled the inclusion criteria during the
study period. Of these, 98 patients were recruited and 8 patients
could not be studied either because they declined to consent to
participate in the study (n=6) or because they returned home to
Lao PDR (across the Mekong River from Thailand) before the
culture became positive and follow up was not possible (n=2). The
age of enrolled patients ranged from 1 day to 92 years (median 39
years). There were 61 (62%) adult and 37 paediatric patients (less
than 18 years) (Table 1). A history of one or more underlying
chronic medical conditions was documented in 57 cases (58%),
with cardiac disease accounting for the greatest proportion (20
cases). A site of infection was identified in 59 (60%) patients.
Repeat blood cultures were performed within 48–96 hours of
the first culture positive for S. aureus in 57 patients (58%,
representing 79% of patients surviving to 4 days), of which 11
(19%) were still positive. After this time period, 56 further blood
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additional 3 patients with persistently positive blood cultures. No
vegetations were seen on transthoracic echocardiography per-
formed on 11 of these 14 patients with persistently positive
cultures. MRSA was responsible for persistently positive cultures
significantly more often than MSSA infection (30% versus 8%
respectively (p=0.02)). Eight of 14 patients (57%) were receiving
antibiotic therapy to which the organism was susceptible in vitro at
the time the repeat blood culture was taken.
Prevalence of endocarditis
Echocardiography was performed in 49 out of 98 patients
(50%). Although the aim of the study was to perform echocardi-
ography on all patients, the remaining 49 patients were either
discharged or died before an echocardiogram could be performed,
were too sick to be taken to the echocardiography room, had a
contraindication to transthoracic echocardiography, or the
echocardiography machine or trained personnel were not
available. However, there were no significant differences between
those who did and did not undergo echocardiography in terms of
pre-disposing cardiac conditions, co-morbidities, immunocompro-
mise, age or presence of prosthetic material (data not shown).
Seven of the 49 patients (14%) undergoing echocardiography had
vegetations visualized. The affected valves were mitral (n=3),
aortic (n=3) and tricuspid (n=1). Two patients had definite
endocarditis and 5 had possible endocarditis by modified Duke
criteria [10], since taking 2 blood culture bottles is uncommon in
the hospital. Among these 7 patients with endocarditis, 1 died.
One additional patient with a history of injection drug use met
clinical criteria for endocarditis, but died before echocardiography
could be performed.
Healthcare exposure
Over half of the infections (54%) were either nosocomial or non-
nosocomial healthcare-associated. Nosocomial infections were
most common in those aged less than 1 year old, accounting for
94% of cases. Infections related to devices were the third most
common site of infection, accounting for 14% of all sites.
Antibiotic resistance and therapy
MRSA accounted for 28% (n=27) of SAB, with no significant
difference in rate between adults and children (26% versus 30%
respectively; p=0.82). The MRSA cases were either nosocomial
(n=21, 78%) or non-nosocomial healthcare-associated (n=6,
22%). Of the 71 MSSA cases, 44 (62%) were community-
acquired, 8 (11%) were non-nosocomial healthcare-associated, and
19 (27%) were nosocomial. There was a significant difference in
MRSA rates on the intensive care units compared with the general
wards: 57% versus 16%, respectively (p,0.001). The impact of
MRSA on effective prescribing of antibiotic therapy is summarised
in Table 2. Patients infected with MSSA were more likely than
patients infected with MRSA to receive an antibiotic to which the
organism was susceptible before the culture results became
available (67/71 (94%) versus 4/27 (15%) respectively,
p,0.001). The median number of days to starting antibiotic
therapy to which the organism was susceptible in vitro was 0
(interquartile range (IQR) 0–0) days and 3 (IQR, 2–4) days for
MSSA and MRSA, respectively (p,0.001). Once culture results
were available, 70 out of 73 survivors (96%) received an antibiotic
that covered the infecting isolate. The median duration of
parenteral treatment given to survivors from the day the first
culture positive for S. aureus was taken was 17 (IQR 12–24) days,
with no difference in duration for patients infected with MSSA
versus MRSA (p=0.26). All MRSA isolates were susceptible to
Table 1. Patient characteristics.
All patients (n=98)
Number of patients (percent)
Demographics
Age (years), median (interquartile range) 39 (9–65)
Sex (male) 57 (58%)
Thai nationality 96 (98%)*
1
Co-morbidities
Prematurity/ Very low birth weight 5 (5%)
Intravenous drug use 4 (4%)
Underlying medical conditions*
2 57 (58%)
- Cardiac disease 20 (20%)
- Diabetes mellitus 12 (12%)
- Renal disease 11 (11%)
- Immunosuppression*
3 11 (11%)
- Lung disease 6 (6%)
Place of acquisition
Community-acquired 44 (45%)
Nosocomial 40 (41%)
Non-nosocomial healthcare-associated 14 (14%)
Types of disease
No identified site of infection 39 (40%)
1 identified site of infection 46 (47%)
.1 identified site of infection 13 (13%)
Sites of infection*
4 All sites (n=73)
Number of sites (percent)
Skin and soft tissue infections 18 (25%)
Pneumonia 12 (16%)
Device-related infections*
5 10 (14%)
Endocarditis*
6 8 (11%)
Septic arthritis 7 (10%)
Post-operative mediastinitis*
7 4 (5%)
Other lung infections*
8 4 (5%)
Solid organ abscess*
9 3 (4%)
Osteomyelitis 2 (3%)
Pyomyositis 2 (3%)
Diabetic foot infections 2 (3%)
Urinary tract infection 1 (1%)
*1Two patients were from Lao PDR.
*2History of any underlying chronic medical condition documented in the
medical notes.
*3Immunosuppression from chemotherapy (n=4), untreated leukaemia (n=1),
HIV (n=3, none of whom were on anti-retroviral therapy or any prophylactic
antibiotics) or immunosuppressive medication including prednisolone
.30 mg/day for .1 week (n=4; one of these additionally on chemotherapy).
*4Denominator is number of sites (n=73) since some patients had .1 site of
infection.
*5Intravenous catheters (central n=3, peripheral n=2, umbilical n=1),
pacemakers (n=3) and arteriovenous graft (n=1).
*6Vegetations on transthoracic echocardiography (n=7); or strong clinical
evidence in intravenous drug user (n=1).
*7Following mitral valve replacement (n=3), or coronary artery bypass graft
(n=1).
*8Empyema (n=2), septic emboli to the lungs (n=1), lung abscesses (n=1).
*9Liver (n=2), spleen (n=1).
doi:10.1371/journal.pone.0004308.t001
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ml). Of the 17 patients with normal renal function who received
vancomycin, 13 (76%) received adequate vancomycin doses by
manufacturer’s recommendations. Measurement of vancomycin
drug levels was not available in the hospital.
Antibiotic resistance patterns are summarised in Table 3. Over
90% of MRSA isolates were resistant to ciprofloxacin, erythro-
mycin, gentamicin, netilmicin, tetracycline and trimethoprim-
sulphamethoxazole, and 65% were resistant to clindamycin.
Vancomycin and fusidic acid had the lowest rates of resistance.
Mortality
The overall mortality rate at 12 weeks was 52% (n=51), and the
S. aureus attributable mortality rate was 44% (n=43). There was
insufficient information to determine the cause of death in 1 case.
Most deaths (39/51, 76%) occurred in hospital or at home on the
day of discharge, as relatives commonly take moribund patients
home to die (n=12). S. aureus bacteraemia accounted for 1% of all
in-patient deaths at Sappasithiprasong hospital during the study
period. Overall mortality increased significantly with age
(p,0.001) (Figure 1). There was a significant difference between
the overall mortality rate in children compared to adults (32%
versus 64%, p=0.003). The association between overall mortality
and increasing age remained highly significant when adjusted for
underlying co-morbidities or immunosuppression (p=0.001). The
mortality rates for MRSA and MSSA were 67% (18/27) and 46%
(33/71), respectively (p=0.11). There was no significant difference
in mortality between patients with and without identified sites of
infection, (47% and 59% respectively, p=0.31). Mortality
amongst patients with repeated blood cultures positive for S.
aureus was 43% (6/14). The median number of days to death in
those patients whose death was attributable to S. aureus was 3
(IQR, 1–6) days compared with 47 (IQR, 25–68) days in those
with non-attributable deaths (p,0.001). Significant differences
were noted on survival curve analysis of attributable mortality
rates in adults and children (p=0.01) (Figure 2), and in the timing
of death for S. aureus attributable and non-attributable deaths
(p=0.001) (Figure 3). There was no difference in times to death
comparing patients infected with MSSA versus MRSA (data not
shown). At 12 weeks, 44 patients (45%) were cured, and 3 patients
(3%) had unresolved infection (empyema thoracis, infected
pacemaker, and osteomyelitis).
Discussion
This study shows that SAB is an important cause of morbidity
and mortality in northeast Thailand. The all-cause and S. aureus-
attributable mortality rates in our study, 52% and 44%
respectively, are considerably higher than mortality rates for
SAB reported from temperate industrialised countries [5–7]. A
Table 2. Impact of MRSA on effective antibiotic prescribing.
All patients (n=98) MSSA*
1 (n=71) MRSA*
1 (n=27) p value*
2
Number of patients (percent)
Pre-culture results
Antibiotic therapy prescribed 93 (95%) 67 (94%) 26 (96%) .0.99
Infecting strain of S. aureus susceptible to prescribed
antibiotic
71 (72%) 67 (94%) 4 (15%) ,0.001
Optimal antibiotic therapy*
3 25 (26%) 23 (32%) 2 (7%) 0.01
Post-culture results*
4 All patients (n=73) MSSA (n=50) MRSA (n=23)
Antibiotic therapy prescribed 72 (99%) 49 (98%) 23 (100%) .0.99
Infecting strain of S. aureus susceptible to prescribed
antibiotic
70 (96%) 48 (96%) 22 (96%) .0.99
Optimal antibiotic therapy*
3 53 (73%) 32 (64%) 21 (91%) 0.02
*1MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus.
*2p value comparing MSSA and MRSA groups.
*3Optimal therapy defined as cloxacillin for MSSA infection and vancomycin for MRSA infection. Alternative therapy used included ceftriaxone, cefazolin, cefoxitin,
ceftazidime, augmentin and ampicillin combined with gentamicin.
*4Denominator is patients who survived to day of culture result. A total of 25 patients (21 with MSSA and 4 with MRSA) died or were discharged moribund priort o
culture results becoming available.
doi:10.1371/journal.pone.0004308.t002
Table 3. Antibiotic resistance rates for infecting isolates.
Antibiotic
All isolates
(n=81)
MSSA*
1
(n=58)
MRSA*
1
(n=23)
Number of resistant isolates (%)
Chloramphenicol 8 (10%) 4 (7%) 4 (17%)
Ciprofloxacin 22 (27%) 1 (2%) 21 (91%)
Clindamycin 16 (20%) 1 (2%) 15 (65%)
Erythromycin 25 (31%) 2 (3%) 23 (100%)
Fusidic acid 42 (52%) 39 (67%) 3 (13%)
Gentamicin 23 (28%) 0 23 (100%)
Mupirocin 7 (9%) 2 (3%) 5 (22%)
Netilmicin 21 (26%) 0 21 (91%)
Penicillin 80 (99%) 57 (98%) 23 (100%)
Rifampicin 8 (10%) 0 8 (35%)
Tetracycline 56 (69%) 34 (59%) 22 (96%)
Trimethoprim-
sulphamethoxazole
22 (27%) 0 22 (96%)
Vancomycin 0 0 0
*1MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus.
doi:10.1371/journal.pone.0004308.t003
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all-cause and attributable mortality of 22% (157/724) and 12%
(86/724), respectively, but this excluded deaths that occurred
before culture results were available. The addition of these cases
would have given an all-cause and S. aureus-attributable mortality
rate of 33% and 23%, respectively. Published studies of all-cause
bacteraemia in Asia have identified S. aureus as a major cause of
bacteraemia, accounting for both community-acquired and
hospital-acquired disease [11–13]. If our data showing that S.
aureus accounts for 1% of all in-patient deaths is representative of
this populous region (half the world’s population lives within
2000 miles of northeast Thailand), then S. aureus would be a major
contributor to preventable mortality worldwide. To our knowledge
this is the first published prospective study to focus on SAB in
tropical Asia. This is noteworthy because papers describing all-
cause bacteraemia in Asia rarely give details by causative
organism, resulting in an under-appreciation of the morbidity
and mortality burden due to S. aureus in the tropics. Sappasithipra-
Figure 1. The burden of S. aureus bacteraemia is highest at the extremes of age, whilst mortality increased with age. Age distribution
and age-specific mortality rates and disease burden for 98 cases of S. aureus bacteraemia studied in Ubon Ratchathani, NE Thailand. Overall mortality
increased significantly with age (p,0.001), analysing age as a continuous variable.
doi:10.1371/journal.pone.0004308.g001
Figure 2. Survival from S. aureus bacteraemia is worse in adults than in children. Kaplan-Meier survival curves comparing adult and
paediatric patients with respect to S. aureus attributable deaths (p=0.01). Non-attributable deaths were censored.
doi:10.1371/journal.pone.0004308.g002
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referrals from clinics and hospitals in the province, but also
provides primary care services to a large local population so
accurate estimates of disease incidence were not possible.
In our study, SAB was most common at the extremes of age, a
similar pattern to that described in a temperate industrialised
country [14,15]. Among the 17 patients under 1 year of age, 16
(94%) had hospital-acquired infections and nearly a third (29%)
were premature or very low birth weight babies. This suggests the
particular vulnerability to acquiring nosocomial SAB of children
less than 1 year of age requiring multiple interventions and
prolonged stays in hospital. A higher incidence in those aged
under 1 year and the predominance of nosocomial infections in
this age group has been described in Denmark [14]. The increase
in numbers of cases and mortality with age also mirror the rise in
co-morbidities with age, as noted in Denmark [15].
The broad range of clinical manifestations seen in patients with
SAB in industrialised countries was observed in this series. Our
findings suggest that the burden of S. aureus disease in the tropics
exceed current perceptions, and demonstrate that serious invasive
infections are common. This has an important bearing on
antimicrobial therapy because management of deep infections
and bacteraemia requires effective antimicrobial therapy whereas
drainage of superficial pus collections can result in cure
irrespective of antibiotic therapy [16].
The rapid deterioration and short median time to death (3 days)
of patients dying from S. aureus septicaemia meant that
echocardiograms could not be performed in half of the patients.
However, the prevalence of echocardiographically-confirmed
endocarditis of 14% (7/49) is comparable to that seen in
industrialised countries [8,17], which has important implications
for many tropical countries where restricted or delayed access to
echocardiography is liable to be an issue. Our prevalence may be
an underestimate since those patients who died earlier may have
been more likely to have endocarditis. A quarter of the patients
with endocarditis died, which is at the lower end of the mortality
range reported for S. aureus endocarditis (25–47%) [18] and may
be a further indication that a number of patients who died prior to
echocardiography had undiagnosed endocarditis. The heart valves
affected by endocarditis were predominantly left-sided, which is in
keeping with the low number of intravenous drug users in our
study. Half the patients with endocarditis were teenagers, which is
a younger age group than typically seen in industrialised temperate
countries [18,19] but is described in other tropical countries
[20,21], often as a result of rheumatic heart disease and
uncorrected congenital heart disease. However, none of our
patients with endocarditis had known valvular abnormalities.
MRSA was responsible for nearly one third of cases of SAB, all
of which were healthcare-associated. Although community-
associated MRSA is a major problem elsewhere, we find no
evidence for this in our setting where a clone defined by multilocus
sequence typing as sequence type 239 predominates [22]. Over
half of our patients had healthcare-associated infections which
suggests that SAB in Thailand is strongly related to healthcare,
mirroring industrialised countries [23,24]. Although there are
comprehensive hospital infection control guidelines in Sappasithi-
prasong hospital, implementing these is difficult due to a bed
occupancy rate that often exceeds 100% and a lack of
infrastructure, such as a scarcity of isolation rooms and only two
hand wash basins on each of the general wards. However, alcohol
hand rub is available in the intensive care units. Addressing such
infection control measures would require a significant increase in
investment, although this would be offset by reducing the expense
of nosocomial infections. Our finding that over half the infections
were healthcare-associated indicates that hospital infection control
is an important area for clinical, microbiological and economic
research if improvements are to be made.
Significant delays in receiving effective antibiotic therapy were
seen with MRSA bacteraemia compared with MSSA bacteraemia.
Vancomycin is available in this setting but is not used in the
empiric regimen for a patient with suspected bacterial sepsis unless
they are already known to be MRSA positive. Monitoring of
vancomycin levels is not possible at Sappasithiprasong Hospital,
which may lead doctors to give lower doses to reduce the
perceived risk of toxicity. The mortality rates for patients with
MRSA who received effective and ineffective empirical antibiotics
were 0% and 69%, respectively, indicating the importance of early
effective treatment. There was a median delay in effective
antibiotic therapy of 3 days for MRSA patients. Delays in treating
SAB are known to have an adverse effect on outcome [25]. The
common usage of ampicillin and gentamicin as empirical therapy
in children under the age of 1 year should be revised in light of our
Figure 3. S. aureus attributable deaths occur more rapidly than non-attributable deaths. Kaplan-Meier survival curves comparing S. aureus
attributable deaths and non-attributable deaths (p=0.001).
doi:10.1371/journal.pone.0004308.g003
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all MRSA strains were resistant to gentamicin. Although
alternative antibiotics to vancomycin may be appropriate therapy
for MRSA, in our setting the high rates of resistance found on
susceptibility testing indicate that these alternatives would not be
effective.
This study has demonstrated that S. aureus is a significant
pathogen in northeast Thailand, with comparable clinical
manifestations and a similar endocarditis prevalence but higher
mortality than industrialised countries. The factors contributing to
this high death rate, such as delayed presentation to hospital and
the early management of sepsis, require further evaluation. The
majority of infections were associated with exposure to healthcare
settings and MRSA was associated with a considerable burden of
disease and a high mortality. Revisions to the empirical
prescribing practices to include MRSA therapy could be
associated with significant benefit. An initiative to raise the profile
of infection control is needed, together with work to characterise
the burden and causes of hospital-acquired infections, including
patient-to-patient transmission of MRSA, such that cost-effective
solutions can be devised appropriate to this setting.
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